NCT06418256 Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations
| NCT ID | NCT06418256 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Splenectomy |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2016-10-16 |
| Primary Completion | 2031-10-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2016-10-16 with a primary completion date of 2031-10-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating cells and to trigger an innate and adaptive response in response to these anomalies, the spleen plays a central role in several diseases affecting blood cells, directly or indirectly. The analysis of the splenic clearance of abnormal cells during ex-vivo perfusions made it possible to clarify the pathogenesis of malaria and the role of the spleen in the adaptive immune response. The study's investigative team wishes to extend these explorations to other human diseases in which the spleen is involved, and to evaluate the preventive or curative potential of substances that can modify the perception of blood cells by the spleen (e.g. monoclonal antibodies directed against circulating cells, among other options).
Eligibility Criteria
Inclusion Criteria: * Adult patients * Patient requiring left splenopancreectomy or planned splenectomy regardless of the method or indication Exclusion Criteria: \- The patient notified his doctor of his refusal to recover his spleen and blood volume
Contact & Investigator
Pierre Buffet, MD, PhD
✉ pierre.buffet@aphp.frPierre Buffet, MD, PhD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT06418256 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Splenectomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06418256 currently recruiting?
Yes, NCT06418256 is actively recruiting participants. Contact the research team at pierre.buffet@aphp.fr for enrollment information.
Where is the NCT06418256 trial being conducted?
This trial is being conducted at Clichy, France, Paris, France, Paris, France, Paris, France and 1 additional location.
Who is sponsoring the NCT06418256 clinical trial?
NCT06418256 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Pierre Buffet, MD, PhD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 100 participants.